Progression Free Survival

Image
Top banner braf

Patients achieved superior progression-free survival with BRAFTOVI + cetuximab vs control arm* in both analyses

*Irinotecan based treatment regimen

Median progression-free survival per updated post-hoc analysis (median follow-up 12.8 months)1,13,a

Image
4.3 months (95% CI: 4.1-5.5) BRAFTOVI + cetuximab (n=220) VS 1.5 months (95% CI: 1.5-1.9) FOLFIRI + cetuximab or irinotecan + cetuximab (n=221)

(HR=0.44 [95% CI: 0.35-0.55], P<0.0001)

Median progression-free survival per primary analysis1,a

  • 4.2 months (95% CI: 3.7-5.4) with BRAFTOVI + cetuximab (n=220) vs 1.5 months (95% CI: 1.5-1.7) with FOLFIRI + cetuximab or irinotecan + cetuximab (n=221) (HR=0.40 [95% CI: 0.30-0.55], P<0.0001)

aPFS was assessed by BIRC. Tumour assessments were performed according to RECIST v1.1.1,3

HealthCare Professionals​

This is an international website for BRAFTOVI dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that:

I am Healthcare Professional outside the US and I have read the information above​. 

Patients

This is an international website for BRAFTOVI dedicated to Healthcare professionals.

I am a patient outside the US​